SLC22A17 and B-cell chronic lymphocytic leukemia: CD38 favors survival in CLL cells by activating an AKT/SYK/Mcl-1 signaling pathway [11], while the binding of NGAL to NGAL-R induces the survival of CLL cells by activating an SRC/STAT3/Mcl-1 signaling [18].